HomeCompareEKTAY vs EQR

EKTAY vs EQR: Dividend Comparison 2026

EKTAY yields 2.25% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EQR wins by $1.2K in total portfolio value
10 years
EKTAY
EKTAY
● Live price
2.25%
Share price
$5.74
Annual div
$0.13
5Y div CAGR
33.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$46.6K
Annual income
$7,846.63
Full EKTAY calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — EKTAY vs EQR

📍 EQR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEKTAYEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EKTAY + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EKTAY pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EKTAY
Annual income on $10K today (after 15% tax)
$191.36/yr
After 10yr DRIP, annual income (after tax)
$6,669.64/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, EKTAY beats the other by $2,015.37/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EKTAY + EQR for your $10,000?

EKTAY: 50%EQR: 50%
100% EQR50/50100% EKTAY
Portfolio after 10yr
$47.2K
Annual income
$6,661.11/yr
Blended yield
14.12%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

EKTAY
Analyst Ratings
1
Hold
Consensus: Hold
Altman Z
1.3
Piotroski
4/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EKTAY buys
0
EQR buys
0
No recent congressional trades found for EKTAY or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEKTAYEQR
Forward yield2.25%5.87%
Annual dividend / share$0.13$3.47
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR33.3%15.8%
Portfolio after 10y$46.6K$47.8K
Annual income after 10y$7,846.63$5,475.61
Total dividends collected$23.3K$23.0K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusHoldHold

Year-by-year: EKTAY vs EQR ($10,000, DRIP)

YearEKTAY PortfolioEKTAY Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$11,000$300.10$11,380$679.82$380.00EQR
2$12,181$411.25$13,014$837.25$833.00EQR
3$13,601$567.35$14,961$1,036.20$1.4KEQR
4$15,343$789.20$17,297$1,289.22$2.0KEQR
5$17,526$1,109.05$20,121$1,613.15$2.6KEQR
6$20,331$1,578.24$23,561$2,030.84$3.2KEQR
7$24,035$2,280.85$27,783$2,573.54$3.7KEQR
8$29,076$3,359.15$33,013$3,284.39$3.9KEQR
9$36,174$5,062.63$39,547$4,223.51$3.4KEQR
10$46,553$7,846.63$47,791$5,475.61$1.2KEQR

EKTAY vs EQR: Complete Analysis 2026

EKTAYStock

Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity, a MR-Linac technology; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for advanced image-guided radiation therapy; treatment management solutions; automated and integrated quality assurance solutions; and hardware and software motion management technology. It also provides MOSAIQ Plaza for multidisciplinary cancer care; Elekta Axis Cloud, a managed hosting service; Elekta Studio, an image-guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Venezia applicator that enables the radiation oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; and Geneva, an applicator for cervical cancer treatment. In addition, the company offers Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for neurosurgeons; Leksell Gamma Knife Lightning for accelerated radiosurgery. Further, it provides neurosurgery products comprising Leksell Vantage Stereotactic System for intracranial neurosurgery; and Leksell Stereotactic System or minimally invasive stereotactic neurosurgery. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.

Full EKTAY Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this EKTAY vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EKTAY vs SCHDEKTAY vs JEPIEKTAY vs OEKTAY vs KOEKTAY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.